Compare Quest Diagnostics Inc (DGX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.61. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| DGX | USIG | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Fixed Income |
52-Week High | $216.02 | $52.69 |
52-Week Low | $166.42 | $50.50 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
USIG trades at $50.50, down 0.4% with bearish technical signals from moving averages but oversold RSI readings. The ETF shows consistent dividend distributions with three payments scheduled for mid-2026. Short interest surged 63.4% in April 2026, indicating increased bearish sentiment among traders despite the investment-grade corporate bond focus.
The ETF faces headwinds from rising short interest and bearish technical momentum, though oversold conditions suggest potential near-term stabilization. Investment-grade corporate bond exposure provides relative safety, but interest rate sensitivity remains a key risk factor for fixed income ETFs in the current market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
